Setting the record straight
By Martin H. Johnson,
Reproductive BioMedicine Online
| 12. 01. 2016
This editorial comments on a paper from Chen et al. (2016)), published in this issue of RBM Online, in an attempt to set the record straight after some shoddy scientific journalism. The paper describes the long-term outcomes of experimental treatments involving ooplasmic transfers conducted between 1996 and 2001 at Saint Barnabas Medical Centre, Livingston, New Jersey, USA (Barritt et al., 2001a). It is timely to report these findings in light of (i) a recent report of the birth of a baby after ‘mitochondrial transfer’, and (ii) because the Human Fertilisation and Embryology Authority (HFEA) in the UK is deciding whether to issue a license for treatment by mitochondrial transfer (http://www.hfea.gov.uk/10363.html).
First, the report of the birth of a baby after meiotic metaphase II spindle transfer to alleviate mitochondrial disease came not in a standard journal article, but in the form of an abstract submitted to the recent American Society for Reproductive Medicine (ASRM) meeting (Zhang et al., 2016a). In choosing this route, the authors have unfortunate form – the same authors having used the same...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...